<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="has been conducted to understand the molecular basis of the" exact="SARS-CoV-2 infection" post="and evolution, develop effective therapeutics, antiviral drugs, and vaccines,"/>
 <result pre="Viruses (ICTV) [1â€&quot;4], while the disease termed as an emerging" exact="coronavirus disease 2019" post="(COVID-19). Since then, this virus has spread to every"/>
 <result pre="now SARS-CoV-2 [55]. Currently, the Global Initiative on Sharing All" exact="Influenza" post="Data (GISAID) (http://www.gisaid.org), have analyzed over 75,853 full genomes"/>
 <result pre="diarrhoea [30], but even dysgeusia and anosmia [27, 78]. Moreover," exact="SARS-CoV infection" post="has been reported in the nervous tissue of experimental"/>
 <result pre="and past epidemics and pandemics situations of Ebola, Zika, Nipah," exact="swine flu," post="avian/bird flu led to make tremendous advances in science"/>
 <result pre="that happened with SARS in the 2002â€&quot;2003 outbreak and the" exact="Ebola" post="outbreak in 2014â€&quot;2015 [107]. During this outbreak, special quarantine"/>
 <result pre="There were no unique antiviral treatments available for SARS and" exact="Ebola" post="at the time of outbreaks as situations were beyond"/>
 <result pre="animal models [131, 132], siRNA candidates in viral infections like" exact="Ebola" post="have failed in clinical trials [133]. Oligonucleoside analogues like"/>
 <result pre="The same strategy of convalescent serum was used during the" exact="Ebola" post="virus outbreak in 2014â€&quot;2015 [164]. Plasma-derived from the patients"/>
 <result pre="substantially inhibit the activity of the main protease of the" exact="MERS coronavirus," post="has an excellent inhibitory activity to the main protease"/>
 <result pre="of inducing an immune response in a subject to the" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) are provided. In several embodiments, the immune"/>
 <result pre="et al. [269] 2018-02-13 US9889194B Immunogenic proteins Immunogenic composition for" exact="MERS coronavirus" post="infection Described herein are immunogenic compositions for preventing infection"/>
 <result pre="infection Described herein are immunogenic compositions for preventing infection with" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least"/>
 <result pre="33.Galasiti KankanamalageACKimYDamalankaVCRathnayakeADFehrARMehzabeenNBattaileKPLovellSLushingtonGHPerlmanSet al.Structure-guided design of potent and permeable inhibitors of" exact="MERS coronavirus" post="3CL protease that utilize a piperidine moiety as a"/>
 <result pre="Anesthesiology. 2020; 132(6):1346-1361. 83.GuoY-RCaoQ-DHongZ-STanY-YChenS-DJinH-JTanK-SWangD-YYanYThe origin, transmission and clinical therapies on" exact="coronavirus disease 2019" post="(COVID-19) outbreak - an update on the statusMil Med"/>
 <result pre="in designing and developing vaccines, drugs, and therapies to counter" exact="Ebola" post="virusFront Immunol180320189 98.MunjalAKhandiaRDhamaKSachanSKarthikKTiwariRMalikYSKumarDSinghRKIqbalHAdvances in developing therapies to combat Zika"/>
 <result pre="Med Infect Dis20161415626879565 106.QiuHBLiXYDuBKangHYJWangYSWangFSunBTongZHThe keypoints in treatment of the critical" exact="coronavirus disease 2019" post="patient(1)Zhonghua Jie He He Hu Xi Za Zhi202043427327732087621 107.SinghRKDhamaKMalikYSRamakrishnanMAKarthikKKhandiaRTiwariRMunjalASaminathanMSachanSet"/>
 <result pre="inflammatory responses: from mechanisms to potential therapeutic toolsVirol Sin2020816 124.CasadevallAThe" exact="Ebola" post="epidemic crystallizes the potential of passive antibody therapy for"/>
 <result pre="A, Kline S et al: Remdesivir for the Treatment of" exact="Covid-19" post="â€&quot; Preliminary Report. N Engl J Med. 2020. 146.GeversSKwaMSGWijnansEvan"/>
 <result pre="C, Ustianowski A, et al. Dexamethasone in Hospitalized Patients with" exact="Covid-19" post="- Preliminary Report. N Engl J Med. 2020. 153.PatelSKSaikumarGRanaJDhamaJYatooMITiwariRRodrÃ­guez-MoralesAJDhamaKDexamethasone:"/>
 <result pre="with dromedary immune serum in an experimental animal model for" exact="Middle East respiratory syndrome" post="coronavirus infectionJ Virol201589116117612025787284 163.MaranoGVaglioSPupellaSFaccoGCatalanoLLiumbrunoGMGrazziniGConvalescent plasma: new evidence for an"/>
 <result pre="Med201319101313131724013700 172.WangZChenXLuYChenFZhangWClinical characteristics and therapeutic procedure for four cases with" exact="2019 novel coronavirus pneumonia" post="receiving combined Chinese and Western medicine treatmentBioScience Trends2020141646832037389 173.SheahanTPSimsACLeistSRSchÃ¤ferAWonJBrownAJMontgomerySAHoggABabusisDClarkeMOet"/>
 <result pre="za zhi20201001180580732234150 177.FanH-HWangL-QLiuW-LAnX-PLiuZ-DHeX-QSongL-HTongY-GRepurposing of clinically approved drugs for treatment of" exact="coronavirus disease 2019" post="in a 2019-novel coronavirus-related coronavirus modelChin Med J (Engl)202013391051105632149769"/>
 <result pre="respiratory support strategy of severe acute respiratory failure caused by" exact="SARS-CoV-2 infection" post="in childrenZhongguo Dang Dai Er Ke Za Zhi202022318319432204751 196.BaronSADevauxCColsonPRaoultDRolainJ-MTeicoplanin:"/>
 <result pre="Faster Progress for COVID-19 Vaccine Candidate. https://www.fdanews.com/articles/197765-sanofi-reports-faster-progress-for-covid-19-vaccine-candidate. 224.Heaton PM. The" exact="Covid-19" post="vaccine-development multiverse. N Engl J Med. 2020. 225.FolegattiPMBittayeMFlaxmanALopezFRBellamyDKupkeAMairCMakinsonRSheridanJRohdeCet al.Safety"/>
 <result pre="J Med. 2020. 225.FolegattiPMBittayeMFlaxmanALopezFRBellamyDKupkeAMairCMakinsonRSheridanJRohdeCet al.Safety and immunogenicity of a candidate" exact="Middle East respiratory syndrome" post="coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase"/>
 <result pre="to curtail COVID-19Int Immunopharm.202023106924 250.Ibrahim NK: Epidemiologic surveillance for controlling" exact="Covid-19" post="pandemic: challenges and implications. J Infect Public Health. 2020."/>
 <result pre="270.Jiang S DL, Zhou Y, Zhao G: Immunogenic composition for" exact="MERS coronavirus" post="infection. 2018. 271.Kyratsous C SN, Sivapalasingam S: Human antibodies"/>
</results>
